MediWound (MDWD)

Executive Summary

MediWound Ltd. is a biopharmaceutical company specializing in enzymatic debridement for severe burns and chronic wounds. Its lead product, NexoBrid, is approved in multiple markets for eschar removal in adults with deep partial- and full-thickness thermal burns, providing a non-surgical alternative that selectively removes necrotic tissue. The company is also advancing EscharEx, a novel formulation for debriding chronic wounds such as venous leg ulcers (VLU) and diabetic foot ulcers. EscharEx has shown promising Phase 2 results and is currently in Phase 3 development for VLU, with a second Phase 3 trial recruiting. MediWound's strategy combines direct commercialization in select territories and partnerships for broader reach. The company's pipeline also includes early-stage candidates for hard-to-heal wounds and basal cell carcinoma.

Upcoming Catalysts (preview)

• H2 2026EscharEx Phase 3 Venous Leg Ulcer Trial Interim Data Readout65% success
• 2026NexoBrid Approval in Additional Geographies (e.g., Japan or EU label expansion)70% success
• Q4 2026EscharEx Partnership or Licensing Deal for Non-U.S. Markets50% success